Takeda has announced a new cancer research collaboration with Crescendo Biologics worth up to $790 million (644.96 million pounds).
The global multi-target collaboration and licence agreement pertains to the discovery, development and commercialisation of Humabody-based therapeutics for cancer indications with a high unmet medical need.
“Takeda and Crescendo Biologics have allied to collaboratively develop a new range of cancer therapies.“
Crescendo will use its proprietary transgenic platform and engineering expertise to discover and configure Humabody candidates against multiple targets selected by Takeda.
Under the terms of the agreement, Crescendo is eligible to receive up to $36 million in upfront fees, investments, research funding and preclinical milestones, plus up to $754 million in further clinical development, regulatory and sales-based milestone payments.
Takeda, in turn, will receive the right to develop and commercialise Humabody-based therapeutics resulting from the collaboration.
Dr Andrew Plump, chief medical and scientific officer at Takeda, said: "Working together with Crescendo will enable us to leverage its important technology to support Takeda's goal of developing next-generation, highly modular and targeted therapies to treat cancer."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical